The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 204-212

  Li, Fang ^a   Weng, Yan ^a   Wang, Lihui ^a   He, Haibing ^a   Yang, Jingyu ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antitumor activity; Biodistribution; Bufadienolides; Cytotoxicity; Nanostructured lipid carriers; Pharmacokinetics

Indexed keywords

BUFADIENOLIDE DERIVATIVE; CYCLOPHOSPHAMIDE; DEOXYCHOLATE SODIUM; FLUOROURACIL; GLYCEROL STEARATE; MEDIUM CHAIN TRIACYLGLYCEROL; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OLEIC ACID; POLOXAMER; UNCLASSIFIED DRUG; ACYLGLYCEROL; ANTINEOPLASTIC AGENT; DEOXYCHOLIC ACID; DRUG CARRIER; EXCIPIENT; LIPID; NANOMATERIAL; TRIACYLGLYCEROL;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA CELL; BRAIN LEVEL; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HUMAN CELL; KIDNEY; LIQUID; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUSCLE SPASM; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; RAT; SARCOMA; SOLID TUMOR; SPLEEN; STOMACH CARCINOMA; TACHYPNEA; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; IC 50; INTRAVENOUS DRUG ADMINISTRATION; LD 50; METABOLISM; METHODOLOGY; PATHOLOGY; PHARMACEUTICS; RABBIT; SARCOMA 180; TISSUE DISTRIBUTION; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BUFANOLIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; EXCIPIENTS; FEMALE; GLYCERIDES; HEMOLYSIS; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; LIPIDS; MALE; MICE; NANOSTRUCTURES; OLEIC ACID; POLOXAMER; RABBITS; RATS; RATS, WISTAR; SARCOMA 180; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 77953358025     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.04.005     Document Type: Article

References (33)

1. Abdel-Rahman M.A., Ahmed S.H., Nabil Z.I. In vitro cardiotoxicity and mechanism of action of the Egyptian green toad Bufo viridis skin secretions. Toxicol. In Vitro 2010, 24:480-485.
2. Bick R.J., Poindexter B.J., Sweney R.R., Dasgupta A. Effects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sci. 2002, 72:699-709.
3. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1450.
4. Esposito E., Fantin M., Marti M., Drechsler M., Paccamiccio L., Mariani P., Sivieri E., Lain F., Menegatti E., Morari M., Cortesi R. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 2008, 25:1521-1530.
5. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
6. Joshi M.D., Müller R.H. Lipid nanoparticles for parenteral delivery of actives. Adv. Drug Deliv. Rev. 2009, 71:161-172.
7. Junzo S., Satoru S., Akiira S. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm. 2004, 273:75-83.
8. Jung S.H., Lim D.H., Jung S.H., Lee J.E., Jeong K.S., Seong H., Shin B.C. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur. J. Pharm. Sci. 2009, 37:313-320.
9. Kamano Y., Yamashita A., Nogawa T., Morita H., Takeya K., Itokawa H., Segawa T., Yukita A., Saito K., Katsuyama M., Pettit G.R. QSAR evaluation of the Chan Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/51. J. Med. Chem. 2002, 45:5440-5447.
10. Kostakis C., Byard R.W. Sudden death associated with intravenous injection of toad extract. Forensic Sci. Int. 2009, 188:e1-5.
11. Krenn L., Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998, 48:1-29.
12. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47:65-81.
13. Krylov V.N. Study of cardiotonic effect of venom of the green toad Bufoviridis. J. Evol. Biochem. Physiol. 2002, 38:223-228.
14. Li F., Wang T., He H.B., Tang X. The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization. Int. J. Pharm. 2008, 349:291-299.
15. Li F., Wang Y., Liu Z., Lin X., He H., Tang X. Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers. Drug Dev. Ind. Pharm. 2010, 10.3109/03639040903264397.
16. Li F., Yang R., Weng Y., Tang X. Preparation and evaluation of lyophilized liposome-encapsulated bufadienolides. Drug Dev. Ind. Pharm. 2009, 35:1048-1058.
17. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Contr. Release 2005, 107:215-228.
18. Miglietta A., Cavalli R., Bocca C., Gabriel L., Gasco M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int. J. Pharm. 2000, 210:61-67.
19. Müller R.H., Rühl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
20. Müller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 2007, 59:522-530.
21. Owens D.E, Peppas N.A. Opsonization, biodistration and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
22. Qin T.J., Zhao X.H., Yun J., Zhang L.X., Ruan Z.P., Pan B.R. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J. Gastroenterol. 2008, 14:5210-5216.
23. Savić R., Luo L., Eisenberg A., Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003, 300:615-618.
24. Schubert M.A., Harms M., Müller-Goymann C.C. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur. J. Pharm. Sci. 2006, 27:226-236.
25. Shimizu Y., Morishita S. Metabolism and disposition of kyushin, a drug containg senso (ch'an su). Am. J. Chin. Med. 1996, 24:289-303.
26. Soma C.E., Dubernet C., Barratt G., Benita S., Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Contr. Release 2000, 68:283-289.
27. Steyn P.S., van Heerden F.R. Bufadienolides of plant and animal origin. Nat. Prod. Rep. 1998, 15:397-413.
28. Terness P., Navolan D., Dufter C., Kopp B., Opelz G. The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity. Int. Immunopharmacol. 2001, 1:119-134.
29. Toma S., Hirai Y., Sugimoto C., Shoji M., Oguni Y., Morishita S., Ito C., Horie M. Metabolic fate of bufalin and cinobufagin. Yakugaku Zasshi 1991, 111:687-694.
30. Wissing S.A., Kayser O., Müller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
31. Yeh J.Y., Huang W.J., Kan S.F., Wang P.S. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003, 54:112-124.
32. Zhang L.S., Yoshida T., Aoki K., Kuroiwa Y. Metabolism of cinobufagin in rat liver microsomes. Identification of epimerized and deacetylated metabolites by liquid chromatography/mass spectrometry. Drug Metab. Dispos. 1991, 19:917-919.
33. Zhang Y., Tang X., Liu X.L., Li F., Lin X. Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chim. Acta 2008, 610:224-231.